Peer-influenced content. Sources you trust. No registration required. This is HCN.

Articles related to IMMUNOTHERAPY

Cancer Therapy Advisor

Sintilimab Provides ‘Robust’ Survival Benefit in Advanced Non-Small Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

Cancer Therapy Advisor

Neoadjuvant Nivolumab Plus Chemo Deemed New Standard Care for Resectable Non-Small Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022

OBR Oncology

BMS Provides Update on CheckMate-901 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Patients with Unresectable or Metastatic Urothelial Carcinoma

Oncology, Medical May 25th 2022

Clinical Advances in Hematology & Oncology

CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL): A Comprehensive Review

Oncology, Medical May 25th 2022

OBR Oncology

Roche Cancer Immunotherapy Fails Another Trial, Casting Doubt On Emerging Drug Class

Oncology, Medical May 25th 2022

Journal of Clinical Oncology

COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer (NSCLC)

Oncology, Medical May 25th 2022